Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company bit.ly/3OYVIbv @Ceapro_Inc $CZO $AEZS

We are a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products. $AEZS #NMOSD #ParkinsonsDisease #ALS #AGHD #CGHD #Hypoparathyroidism #Diagnostics #Therapeutics #AutoimmuneDiseases

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings bit.ly/3IxCJ4c $AEZS $CZO @ceapro_inc #Diagnostics #Therapeutics

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency bit.ly/3xkazqU $AEZS #Diagnostics #Therapeutics

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris bit.ly/3TQGwjv $CZO $AEZS @Ceapro_inc #Diagnostics #Therapeutics

Aeterna Zentaris Announces Effective Date of Share Consolidation bit.ly/4dhHa17 $AEZS #Diagnostics #Therapeutics

Stay up to date on $AEZS news and events by signing up for our email alerts here: bit.ly/3BG4lRZ #NMOSD #ParkinsonsDisease #ALS #AGHD #CGHD #Hypoparathyroidism #Diagnostics #Therapeutics #AutoimmuneDiseases

Stay up to date on news regarding our merger here: bit.ly/3Q5WELT $AEZS $CZO #NMOSD #ParkinsonsDisease #ALS #AGHD #CGHD #Hypoparathyroidism #Diagnostics #Therapeutics #AutoimmuneDiseases

Aeterna Zentaris Reports First Quarter 2024 Financial Results bit.ly/44KhpCN $AEZS #diagnostics #therapeutics

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro bit.ly/3wv5L2b #diagnostics #Therapeutics $AEZS $CZO

Visit our website at bit.ly/3BL7gpx to learn more about our pursuit of medical innovations. $AEZS #NMOSD #ParkinsonsDisease #ALS #AGHD #CGHD #Hypoparathyroidism #Diagnostics #Therapeutics #AutoimmuneDisease

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date bit.ly/3Kp7HMI $AEZS

Access investor resources here: bit.ly/3SIKvgc $AEZS #NMOSD #ParkinsonsDisease #ALS #AGHD #CGHD #Hypoparathyroidism #Diagnostics #Therapeutics #AutoimmuneDiseases

Aeterna Zentaris and Ceapro Complete Merger Transaction bit.ly/4bYwVxa $AEZS $CZO #Diagnostics #Therapeutics

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency bit.ly/45l54p5 $AEZS #Diagnostics #GrowthHormoneDeficiency #GrowthHormone

Stay up to date on $AEZS news and events by signing up for our email alerts here: bit.ly/3BG4lRZ #NMOSD #AGHD #CGHD #Hypoparathyroidism #Diagnostics #Therapeutics #AutoimmuneDiseases #oatbetaglucan #avenanthramides #lifesciences #plantbased #PGXtechnology

#Reminder for all shareholders to join us for our Annual Meeting today at 10 AM ET. Shareholders can access the meeting by visiting: bit.ly/4bo7ZPf $AEZS #Diagnostics #Therapeutics #plantbased #PGXtechnology

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders bit.ly/4cJFFrN $AEZS #Diagnostics #Therapeutics

Visit our website at bit.ly/3BL7gpx to learn more about our pursuit of medical innovations. $AEZS #NMOSD #AGHD #CGHD #Hypoparathyroidism #Diagnostics #Therapeutics #AutoimmuneDiseases #oatbetaglucan #avenanthramides #lifesciences #plantbased #PGXtechnology

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. bit.ly/3LXAFEc $AEZS #Diagnostics #Therapeutics